clinical trial · NCT06585202
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic DermatitisATI-2138
brief summary
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
started
Aug 19, 2024
primary completion
Mar 13, 2025
completion
Mar 31, 2025
last updated
Mar 12, 2026
detailed description
This open-label, single-arm study of ATI-2138 in moderate to severe AD participants between the ages of 18 and 60 years (inclusive) will investigate the safety, tolerability, pharmacokinetics, efficacy and pharmacodynamics of ATI-2138 administered over 12 weeks.
official title
A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol